Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;97(6):1091-1093.
doi: 10.1016/j.kint.2020.04.009. Epub 2020 Apr 14.

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2

Francois Alhenc-Gelas  1 , Tilman B Drueke  2
Affiliations
Comment

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2

Francois Alhenc-Gelas et al. Kidney Int. 2020 Jun.
No abstract available

Keywords: ACE2; COVID-19; renin-angiotensin system; viral infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of the renin-angiotensin system and the possible roles of SARS-CoV-2 binding to ACE2 in COVID-19. (Left, middle) The physiological steps of the generation of angiotensin II and angiotensin 1-7 and their actions on specific receptors are shown. Angiotensin II is generated from angiotensinogen by the actions of renin and subsequently anchored to ACE in the cell membrane. ACE2, another transmembrane enzyme, removes the carboxyterminal amino acid of angiotensin II, thereby inactivating angiotensin II but generating angiotensin 1-7 with biological activity distinct from angiotensin II. Angiotensin 1-7 activates the Mas receptor. (Right) The interaction of circulating SARS-CoV-2 with ACE2 is depicted. Membrane-bound ACE2 serves as the exclusive (or at least main) SARS-CoV-2 receptor, allowing host cell entry and infection via virus binding to the S1 domain of the viral Spike protein. In addition to its full-length transmembranous form, ACE2 also exists in soluble form (sACE2) in the circulation, lacking its membranous anchor. According to recent studies, increasing bioavailability of sACE2 by administering recombinant human sACE2 may act as a virus trap and inactivator.,
See this image and copyright information in PMC

Comment on

References

    1. Wrapp D., Wang N., Corbett K.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. - PMC - PubMed
    1. Wan Y., Shang J., Graham R. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94 e00127-20. - PMC - PubMed
    1. Danilczyk U., Penninger J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res. 2006;98:463–471. - PubMed
    1. Varagic J., Ahmad S., Nagata S. ACE2: angiotensin II/angiotensin-(1–7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16:420. - PMC - PubMed
    1. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 [e-pub ahead of print]. Cell. https://doi.org/10.1016/j.cell.2020.04.004. Accessed April 2, 2020. - DOI - PMC - PubMed

Substances